Ma, Bo <br/><br/>
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.  [electronic resource] 

 -  Acta pharmacologica Sinica  Apr 2012 
 - 479-89 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1745-7254 
<br/><br/><label>Standard No.: </label>10.1038/aps.2011.177  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bone Density--drug effects<br/>Bone and Bones--drug effects<br/>Female<br/>Fructosediphosphates--pharmacology<br/>Humans<br/>Immunologic Factors--pharmacology<br/>Insulin-Like Growth Factor I--analysis<br/>Osteoporosis, Postmenopausal--blood<br/>Osteoprotegerin--blood<br/>Oxidative Stress--drug effects<br/>RANK Ligand--blood<br/>Rats<br/>Rats, Sprague-Dawley<br/>Receptor Activator of Nuclear Factor-kappa B--blood<br/>Signal Transduction